Diagnostic Work-Up and Treatment for ATTR Cardiomyopathy
For suspected ATTR-CM, obtain echocardiography showing increased LV wall thickness, screen for plasma cell disorder with serum/urine immunofixation and free light chains, and if negative, proceed directly to 99mTc-PYP bone scintigraphy—grade ≥2 myocardial uptake without a monoclonal protein is diagnostic and eliminates the need for endomyocardial biopsy; once diagnosed, initiate tafamidis immediately as it improves survival and functional capacity. 1
Diagnostic Algorithm
Step 1: Clinical Suspicion - Red Flags
Look for these specific clinical features that should trigger ATTR-CM evaluation 1, 2:
- Cardiac: Unexplained LV wall thickening (≥12mm), heart failure with preserved ejection fraction (HFpEF) of unclear cause, low-voltage ECG despite increased wall thickness, atrial fibrillation with heart failure
- Extracardiac: Bilateral carpal tunnel syndrome (especially preceding heart failure by years), lumbar spinal stenosis, autonomic neuropathy (orthostatic hypotension, erectile dysfunction), unexplained peripheral neuropathy
- Demographics: Age >60 years, male predominance (particularly for wild-type ATTR)
Step 2: Initial Diagnostic Testing
When ATTR-CM is suspected 1:
- Echocardiography: Look for increased LV wall thickness, granular sparkling appearance, biatrial enlargement, reduced global longitudinal strain with apical sparing
- Cardiac MRI (if available): Diffuse late gadolinium enhancement, elevated extracellular volume fraction
- ECG: Low voltage relative to wall thickness, pseudoinfarct pattern
- Biomarkers: Elevated NT-proBNP and troponin (for staging, not diagnosis)
Step 3: Exclude Light Chain Amyloidosis
This step is mandatory before proceeding 1:
- Serum and urine immunofixation electrophoresis
- Serum free light chain assay
- If any monoclonal protein is detected, hematology referral is required to rule out AL amyloidosis
Step 4: Bone Scintigraphy (Non-Invasive Diagnosis)
If no monoclonal protein is found 1:
- Perform 99mTc-PYP (or DPD/HMDP outside US) cardiac scintigraphy
- Grade ≥2 myocardial uptake + absence of monoclonal protein + appropriate cardiac imaging = diagnostic for ATTR-CM
- Endomyocardial biopsy is NOT needed when these criteria are met
Step 5: TTR Gene Sequencing
Perform in ALL diagnosed ATTR-CM patients 1:
- Differentiates wild-type (ATTRwt) from hereditary (ATTRm)
- Required even without family history due to variable penetrance
- If variant detected, genetic counseling for family members is indicated
Step 6: Biopsy (Only If Needed)
Endomyocardial or extracardiac biopsy with Congo red staining is reserved for 1:
- Equivocal scintigraphy results
- Presence of monoclonal protein requiring differentiation from AL amyloidosis
- Tissue must undergo immunofluorescence or mass spectrometry to confirm ATTR subtype
Treatment Recommendations
Disease-Modifying Therapy
Tafamidis is the primary disease-modifying treatment with Class 1 recommendation 3:
- TTR stabilizer that prevents tetramer dissociation
- Proven mortality benefit and improved functional capacity
- Initiate early in disease course for maximum benefit 4, 5
- More effective when started before advanced cardiac dysfunction develops
Additional Treatment Options Under Development 5, 6, 7:
- TTR gene silencers: Patisiran, vutrisiran, eplontersen (suppress hepatic TTR synthesis)
- Acoramidis: Alternative TTR stabilizer
- Gene editing: Nexiguran ziclumeran (CRISPR-Cas9 technology, single-dose potential)
- Monoclonal antibodies: Cormitug, ALXN220, AT-02 (target amyloid removal—major unmet need)
Supportive Heart Failure Management
Standard heart failure therapies with important caveats:
- Diuretics: For volume management (often require higher doses)
- Avoid or use cautiously: Digoxin (binds to amyloid fibrils), calcium channel blockers, beta-blockers (may worsen conduction abnormalities)
- Arrhythmia management: High prevalence of atrial fibrillation; consider anticoagulation regardless of CHA₂DS₂-VASc score
- Pacemaker/ICD: For conduction disease or ventricular arrhythmias as indicated
Monitoring Treatment Response 3
Assess efficacy using combination of:
- Biomarkers: NT-proBNP, cardiac troponins, eGFR
- Imaging: Echocardiographic global longitudinal strain, CMR extracellular volume fraction
- Clinical metrics: Functional status (6-minute walk test), hospitalizations, survival
Prognostic Stratification
Staging system for ATTR-CM 1:
- Stage 1: NT-proBNP <3000 pg/mL AND eGFR ≥45 mL/min
- Stage 2: One threshold met
- Stage 3: NT-proBNP ≥3000 pg/mL AND eGFR <45 mL/min
Higher stages correlate with worse prognosis; untreated median survival is 2-6 years from diagnosis.
Critical Pitfalls to Avoid
- Misdiagnosis as hypertrophic cardiomyopathy or HFpEF: Always consider ATTR-CM in older patients with unexplained LV hypertrophy 1
- Delaying diagnosis: Treatment is more effective early; don't wait for advanced symptoms 4, 8
- Skipping monoclonal protein screening: Cannot diagnose ATTR-CM without excluding AL amyloidosis 1
- Performing unnecessary biopsies: Grade ≥2 PYP uptake without monoclonal protein is diagnostic 1
- Not genotyping diagnosed patients: Essential for family counseling and understanding prognosis 1
- Withholding treatment due to cost concerns: Individual patient benefit in survival and symptoms justifies therapy 3
Multidisciplinary Care Model
ATTR-CM management requires collaboration 3:
- Primary care providers for initial recognition
- Community cardiologists for initial workup
- Amyloid specialists at referral centers for complex cases
- Telehealth expanding access to specialists, particularly for rural/underserved populations